Nykredit A S Invests $14.27 Million in Waters Corporation $WAT

Nykredit A S purchased a new position in Waters Corporation (NYSE:WAT) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 38,061 shares of the medical instruments supplier’s stock, valued at approximately $14,274,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Anchor Investment Management LLC acquired a new position in shares of Waters in the 1st quarter worth approximately $27,000. Resources Management Corp CT ADV acquired a new stake in shares of Waters during the 1st quarter valued at approximately $27,000. PenderFund Capital Management Ltd. bought a new position in Waters during the second quarter worth $28,000. Zions Bancorporation National Association UT boosted its holdings in Waters by 121.2% in the fourth quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 40 shares during the period. Finally, Vision Retirement LLC acquired a new position in Waters in the first quarter worth $29,000. 94.01% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Waters news, Director Christopher Kuebler sold 3,626 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $397.94, for a total transaction of $1,442,930.44. Following the transaction, the director owned 17,808 shares of the company’s stock, valued at approximately $7,086,515.52. This trade represents a 16.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Guggenheim reissued a “buy” rating and set a $440.00 target price on shares of Waters in a report on Wednesday, July 8th. Wolfe Research initiated coverage on Waters in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $425.00 price objective for the company. Weiss Ratings downgraded Waters from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, August 12th. Wall Street Zen raised Waters from a “hold” rating to a “buy” rating in a research report on Saturday, August 29th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $400.00 target price on shares of Waters in a research note on Wednesday, August 5th. Three research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $424.35.

Key Headlines Impacting Waters

Here are the key news stories impacting Waters this week:

• Positive Sentiment: Shares are up 3.1% since the company’s most recent earnings report, reflecting investor confidence after Waters exceeded quarterly expectations with adjusted EPS of $3.05 versus the $3.01 consensus and revenue of $1.65 billion versus $1.62 billion expected. Why Is Waters Up Since Last Earnings Report?
• Positive Sentiment: Analysts currently assign Waters a consensus recommendation of “Moderate Buy,” providing continued support for the stock. The company also maintained 2026 earnings guidance of $14.45 to $14.65 per share. Waters Given Moderate Buy Recommendation
• Neutral Sentiment: Waters’ latest results included strong reported year-over-year revenue growth and an earnings beat, but investors may focus on whether that momentum is sustainable and whether the company can deliver its full-year outlook.
• Negative Sentiment: The stock trades at a very elevated valuation—approximately 102 times earnings—so expectations are high. Any weaker-than-expected demand, guidance revision, or margin pressure could produce volatility despite the positive analyst consensus.

Waters Trading Down 1.0%

Shares of WAT stock opened at $409.39 on Friday. Waters Corporation has a 1 year low of $282.77 and a 1 year high of $426.22. The firm has a market capitalization of $40.22 billion, a PE ratio of 102.09, a price-to-earnings-growth ratio of 2.41 and a beta of 1.19. The stock has a fifty day moving average of $391.93 and a two-hundred day moving average of $351.45. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.29 and a current ratio of 1.86.

Waters (NYSE:WAT) last issued its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 EPS for the quarter, beating analysts’ consensus estimates of $3.01 by $0.04. Waters had a return on equity of 11.27% and a net margin of 3.58%.The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.62 billion. During the same period last year, the company earned $2.95 earnings per share. The company’s quarterly revenue was up 113.3% compared to the same quarter last year. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. As a group, research analysts expect that Waters Corporation will post 14.56 EPS for the current year.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.